KRAS and colorectal cancer: an important step to the personalized medicine;KRAS et cancer colorectal : un pas de géant vers la médecine personnalisée

Immuno-Analyse et Biologie Specialisee

Volumn 24, Issue 4, 2009, Pages 196-209

  Lamoril, J ^c   Ameziane, N ^a   Deybach, J C ^c   Bouizegarene P ^c   Bogard, M ^b  

^a Laboratoire de biologie polyvalente   (France)

^b CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^c HÔPITAL LOUIS MOURIER   (France)

Author keywords

Anti EGFR; Cetuximab; Colorectal cancer; KRAS; Panitumumab

Indexed keywords

APC PROTEIN; B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; LAPATINIB; MATUZUMAB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MLH1; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN; ZALUTUMUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER MORTALITY; CANCER RESISTANCE; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; FRANCE; GENE MUTATION; HUMAN; METASTASIS; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 70349482087     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2009.05.001     Document Type: Short Survey

References (81)

1. Allegra C.J., Jessup J.M., Somerfield M.R., Hamilton S.R., Hammond E.H., Hayes D.F., et al. American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol (2009)
2. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008) 1626-1634
3. Aoki Y., Niihori T., Narumi Y., Kure S., and Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 29 (2008) 992-1006
4. Artale S., Sartore-Bianchi A., Veronese S.M., Gambi V., Sarnataro C.S., Gambacorta M., et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26 (2008) 4217-4219
5. Barault L., Veyrie N., Jooste V., Lecorre D., Chapusot C., Ferraz J.M., et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122 (2008) 2255-2259
6. Barber T.D., Vogelstein B., Kinzler K.W., and Velculescu V.E. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351 (2004) 2883
7. Bazan V., Migliavacca M., Zanna I., Tubiolo C., Grassi N., Latteri M.A., et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13 (2002) 1438-1446
8. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67 (2007) 2643-2648
9. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27(5):663-71.
10. Bos J.L., Fearon E.R., Hamilton S.R., Verlaan-de Vries M., van Boom J.H., van der Eb A.J., and Vogelstein B. Prevalence of RAS gene mutations in human colorectal cancers. Nature 327 (1987) 293-297
11. Bouvier A.M. Épidemiologie descriptive du cancer colorectal en France. Bull Epidemiol Hebdo 2-3 (2009) 14-16
12. Cho N.Y., Choi M., Kim B.H., Cho Y.M., Moon K.C., and Kang G.H. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer 119 (2006) 1858-1862
13. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23 (2005) 1803-1810
14. de Vogel S., Weijenberg M.P., Herman J.G., Wouters K.A., de Goeij A.F., van den Brandt P.A., et al. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. Ann Oncol 20 7 (2009) 1216-1222
15. Dempke W.C., and Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 45 7 (2009) 1117-1128
16. Di Fiore F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M.P., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96 (2007) 1166-1169
17. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26 (2008) 5705-5712
18. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102 (2005) 16368-16373
19. Diehl F., Li M., He Y., Kinzler K.W., Vogelstein B., and Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 3 (2006) 551-559
20. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 14 (2008) 985-990
21. Diehl F., Schmidt K., Durkee K.H., Moore K.J., Goodman S.N., Shuber A.P., et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 135 (2008) 489-498
22. Do H., Krypuy M., Mitchell P.L., Fox S.B., and Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 8 (2008) 142
23. Finkelstein S.D., Sayegh R., Christensen S., and Swalsky P.A. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-RAS-2 mutation type. Cancer 71 (1993) 3827-3838
24. Fleischhacker M., and Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 1775 (2007) 181-232
25. Frayling I.M. Methods of molecular analysis: mutation detection in solid tumours. Mol Pathol 55 (2002) 73-79
26. Fujimoto K., Sheng H., Shao J., and Beauchamp R.D. Transforming growth factor-beta1 promotes invasiveness after cellular transformation with activated RAS in intestinal epithelial cells. Exp Cell Res 266 (2001) 239-249
27. Fujiwara T., Stolker J.M., Watanabe T., Rashid A., Longo P., Eshleman J.R., et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol 153 (1998) 1063-1078
28. Gallegos Ruiz M.I., Floor K., Rijmen F., Grünberg K., Rodriguez J.A., and Giaccone G. EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol 29 (2007) 257-264
29. Garm Spindler K.L., Pallisgaard N., Rasmussen A.A., Lindebjerg J., Andersen R.F., Crüger D., et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 20 5 (2009) 879-884
30. Gautschi O., Huegli B., Ziegler A., Gugger M., Heighway J., Ratschiller D., et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett 254 (2007) 265-273
31. Geigl J.B., Obenauf A.C., Schwarzbraun T., and Speicher M.R. Defining 'chromosomal instability'. Trends Genet 24 (2008) 64-69
32. Goldstein N.S., and Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92 (2001) 1331-1346
33. Grady W.M., and Carethers J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135 (2008) 1079-1099
34. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
35. Halilovic E., and Solit D.B. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol 8 (2008) 419-426
36. Heinemann V., Stintzing S., Kirchner T., Boeck S., and Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev (2008)
37. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009 14(1):22-8.
38. Jimeno A., Messersmith W.A., Hirsch F.R., Franklin W.A., and Eckhardt S.G. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27 (2009) 1130-1136
39. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008) 1757-1765
40. Karnoub A.E., and Weinberg R.A. RAS oncogenes: split personalities. Nat Rev Mol Cell Biol 9 (2008) 517-531
41. Karpinski P., Ramsey D., Grzebieniak Z., Sasiadek M.M., and Blin N. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. Mol Cancer Res 6 (2008) 585-591
42. Kato S., Iida S., Higuchi T., Ishikawa T., Takagi Y., Yasuno M., et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121 (2007) 1771-1778
43. Konishi M., Kikuchi-Yanoshita R., Tanaka K., Muraoka M., Onda A., Okumura Y., et al. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 111 (1996) 307-317
44. Lenz H.J., Van Cutsem E., Khambata-Ford S., Mayer R.J., Gold P., Stella P., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24 (2006) 4914-4921
45. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
46. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9 (2008) 962-972
47. Mayer R.J. Targeted therapy for advanced colorectal cancer--more is not always better. N Engl J Med 360 (2009) 623-625
48. Mendelsohn J., and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21 (2003) 2787-2799
49. Messersmith W.A., and Ahnen D.J. Targeting EGFR in colorectal cancer. N Engl J Med 359 (2008) 1834-1836
50. Monticone M., Biollo E., Maffei M., Donadini A., Romeo F., Storlazzi C.T., et al. Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Mol Cancer 7 (2008) 92
51. Mor A., and Philips M.R. Compartmentalized Ras/MAPK signaling. Annu Rev Immunol 24 (2006) 771-800
52. Niihori T., Aoki Y., Narumi Y., Neri G., Cavé H., Verloes A., et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38 (2006) 294-296
53. Nosho K., Kawasaki T., Ohnishi M., Suemoto Y., Kirkner G.J., Zepf D., et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10 (2008) 534-541
54. Ogino S., Kawasaki T., Brahmandam M., Yan L., Cantor M., Namgyal C., et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7 (2005) 413-421
55. Ogino S., and Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 10 (2008) 13-27
56. Ogino S., Nosho K., Kirkner G.J., Kawasaki T., Meyerhardt J.A., Loda M., et al. CpG island methylator phenotype, microsatellite instability. BRAF mutation and clinical outcome in colon cancer. Gut 58 (2009) 90-96
57. Oliveira C., Westra J.L., Arango D., Ollikainen M., Domingo E., Ferreira A., et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 13 (2004) 2303-2311
58. Osborn N.K., and Ahlquist D.A. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128 (2005) 192-206
59. Peeters M., Price T., and Van Laethem J.L. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?. Oncologist 14 (2009) 29-39
60. Personeni N., Fieuws S., Piessevaux H., De Hertogh G., De Schutter J., Biesmans B., et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 14 (2008) 5869-5876
61. Poehlmann A., Kuester D., Meyer F., Lippert H., Roessner A., and Schneider-Stock R. K-RAS mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 203 (2007) 489-497
62. Raponi M., Winkler H., and Dracopoli N.C. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 8 (2008) 413-418
63. Ravindranath N., Wion D., Brachet P., and Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 22 (2001) 432-443
64. Rivera F., Vega-Villegas M.E., Lopez-Brea M.F., and Marquez R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol 47 (2008) 9-19
65. Rouleau E., Spyratos F., Dieumegard B., Guinebretière J.M., Lidereau R., and Bièche I. KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition. Br J Cancer 99 (2008) 2100
66. Santini D., Loupakis F., Vincenzi B., Floriani I., Stasi I., Canestrari E., et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13 (2008) 1270-1275
67. Sartore-Bianchi A., Martini M., Molinari F., Veronese S., Nichelatti M., Artale S., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69 (2009) 1851-1857
68. Schubbert S., Shannon K., and Bollag G. Hyperactive RAS in developmental disorders and cancer. Nat Rev Cancer 7 (2007) 295-308
69. Simi L., Pratesi N., Vignoli M., Sestini R., Cianchi F., Valanzano R., et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130 (2008) 247-253
70. Stroun M., Lyautey J., Lederrey C., Olson-Sand A., and Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 313 (2001) 139-142
71. Takai Y., Sasaki T., and Matozaki T. Small GTP-binding proteins. Physiol Rev 81 (2001) 153-208
72. Thomas S.M., and Grandis J.R. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30 (2004) 255-268
73. Tol J., Koopman M., Rodenburg C.J., Cats A., Creemers G.J., Schrama J.G., et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19 4 (2008) 734-738
74. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360 (2009) 563-572
75. Tsuchihashi Z., Khambata-Ford S., Hanna N., and Jänne P.A. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 353 (2005) 208-209
76. Velho S., Oliveira C., and Seruca R. KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. J Clin Oncol 27 (2009) 158-159
77. Vincenzi B., Schiavon G., Silletta M., Santini D., and Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol 68 (2008) 93-106
78. Winer E., Gralow J., Diller L., Karlan B., Loehrer P., Pierce L., et al. American Society of Clinical Oncology. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 27 (2009) 812-826
79. Wood L.D., Parsons D.W., Jones S., Lin J., Sjöblom T., Leary R.J., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
80. Woodcock J., and Lesko L.J. Pharmacogenetics--tailoring treatment for the outliers. N Engl J Med 360 (2009) 811-813
81. Workman P., and de Bono J. Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. Curr Opin Pharmacol 8 (2008) 359-362